Peer Review History
| Original SubmissionJuly 16, 2020 |
|---|
|
Transfer Alert
This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.
PONE-D-20-21795 Mycobacterium leprae promotes triacylglycerol de novo synthesis through induction of GPAT3 expression in host macrophages PLOS ONE Dear Dr. Suzuki, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review proce Both reviewers did not agree with your conclusions and felt there were serious flaws that need to be resurrected. This also entails new experiments. Please submit your revised manuscript within 90days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Delphi Chatterjee Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2.PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript entitled ‘Mycobacterium leprae promotes triacylglycerol de novo synsthesis through induction of GPAT3 expression in host macrophages’ by Tanigawa et al; claims to demonstrate that M. leprae infection induces the production of triacylglycerols (TAGs) in a macrophage cell line. Authors linked this host production of TAGs to the function of glycerol-3-phosphagte acyltransferase 3 (GPAT3), which may be essential for intracellular survival of M. leprae within host cells. This is an interesting study working with a difficult pathogen, defining how M. leprae could stimulate the host cell physiology to create an environment that favors its intracellular survival. This study is well conducted and sounded; however, authors have some bold claims that are not well supported by their data. Major concerns are: 1/ Analysis of host lipids performing HPTLC. Although this is a valid technique, a LC/MS analysis will provide a clear picture (and quantification) of all the host lipids that are being altered after M. leprae infection of TH-1 cells. As depicted, authors focused on DAGs/TAGs and the phospholipid fractions (a major fraction in host lipids) is not clearly studied in the solvent system presented (PLs practically did not migrated on the HPTLC from the origin to state that these are not being modified). Moreover, it will be important to add reference standard controls on the HPTLCs to be certain of the nature of the lipids being identified. THP-1 cells lipids and M. leprae lipids alone controls are also missing. Provide also the TLCs in color, so this can be better appreciate it. 2/ In the production of TAGs by host cells it also seems to be a dose dependent effect (different MOIs induced different expression levels at 24 h), but this is not being follow up. Authors, did also not explain why there is a spike of TAG production in THP-1 cells infected with dead M. leprae. 3/ Related to the induction of GPAT3, it will be important to assess if this is induction is M. leprae specific or if other bacteria/mycobacteria induces GPAT3 in Th-1 cell line. For example, M. bovis BCG, M. avium, M. smegmatis, or even M. tuberculosis. 4/ Fig 3C needs better images and with the same background contrast. GPAT3 KO background seems lighter than the WT background making difficult to interpret. A quantification will be also required demonstrating the author’s claim of decrease in lipid formation in GPAT3 cells infected with live M. leprae. 5/ Line 291-292: ‘newly synthesized TAG following M. leprae infection is in turn utilized by M. leprae itself’ There is not conclusive data supporting this statement. Could authors rationalize why other M. leprae lipids are not radioactive and thus not being seeing on the autoradiogram provided? One will be expecting seeing radioactive free fatty acids, DAG, etc. and not only DAG. 6/ Fig. 4A: Quantification by Confocal microscopy counting bacteria per cell is necessary. It will be important to show the flow cytometry plots describing the strategy used removing extracellular FITC-M. leprae bacilli and focusing only in infected cells. Also to show graphs at % of infected vs. non-infected cells. How many times this study was done? 7/ A good control will be to have one of the others GPAT KOs, and further determine that their absence does not affect M. leprae uptake/survival in THP-1 cells. 8/ Lines 379-381: “Together, these results suggest that host GPAT-3-mediated TAG synthesis is responsible for foamy cell formation induced by M. leprae infection, and that GPAT3 activity is necessary for maintaining intracellular parasitization by M. leprae.”This is not proven in this manuscript. The infection went in vitro for 24 h. It may participate in the establishment of the infection in THP-1 cells. 9/ Line 415-416: It is not show that the produced host TAG can be used as a source for mycobacterial lipids and that GPAT3 is essential (would say plays an important role) for intracellular survival of M. leprae. 10/ Discussion: Is the absence of GPAT3 affecting M. leprae replication, survival or both? 11/ Fig 2A does not show what is discussed in the text. 12/ In Fig 2B: It is not clear if the statistical analyses are relative to ACTB, to others GPAT measured, or if these are comparing GPAT3 RNA transcription levels across time. In figure legends, it is not clear how many times these analyses were performed. 13/ Some figure legends have a Scale bar that do not apply. 14/ Animals studies are missing but an ethics statement is provided. Reviewer #2: General comments This article explores the mechanisms by which M. leprae modulates host cell lipid metabolism. The capacity of M. leprae to induce lipid accumulation in infected cells, an aspect that seems to be essential for bacterial pathogenesis, has been demonstrated by several reports during the last two decades. In this study, the authors infected cells of the monocytic cell line THP-1 and based on this model of infection, they concluded that TAG are the major class of lipids accumulated during infection. They also show that M. leprae induces the expression of GPAT3, one of the four isoforms of the enzyme that catalyzes the rate-limiting step in the pathway of TAG biosynthesis. Moreover, by Knocking down the GPAT3 gene in THP-1 cells, they conclude that host TAG is used by M. leprae and that this nutrient source is important for bacterial intracellular survival. Although the subject is relevant and the data generated are original, experiments are incomplete, controls are missing, and alternative methods are needed to validate the conclusions of the study. Importantly, the authors should consider the limitations imposed by their in vitro model based on THP-1 cells and discuss the discrepancies observed between their results and those generated by others along recent years. Specific comments Title In the title it is said that the observations are in infected macrophages, however, this is not thru since no protocol for differentiating THP-1 monocytes into macrophages is mentioned in the methods. This needs to be corrected. Results Figure 1- Results differ from Mattos et al. 2014, in which in human primary monocytes/ macrophages infected with M. leprae in a MOI of 5:1 cholesterol and cholesterol esters are the most abundant lipids and TAG actually decreases with the infection. The cell model is different, and MOI is higher in this work (50:1). This needs to be addressed in the discussion section. Also, tumor cells frequently express a lipogenic phenotype and how this may influence the results observed in THP-1 monocytes should be addressed at some point. Figure 2- From the literature it seems that GPAT1 and 2 are located in the mitochondria, while GPAT3 and 4 are related to LDs. It would be interesting to show the relative basal level of expression of each isoform in THP-1 monocytes. Is GPAT3 the more abundant isoform in this cell line? Figure 3- It would be interesting to show that KO cells of the other GPAT isoforms, specially GPAT4, are not related to TAG biosynthesis in the context of M. leprae infection. This would strengthen the data from the previous figure that only showed modulation of GPAT3 expression. 3C- The quality of the microscopy images is not good. I would also suggest increasing the size. 3E- The conclusion drawn from this experiment that M. leprae utilizes host TAG is not convincing. During cell disruption and M. leprae isolation, TAG molecules could nonspecifically bind to the hydrophobic bacterial cell envelope. This would be more likely to occur in WT cells where the levels of labeled TAG are higher. To rule out this possibility, the inclusion of a control in which heat-killed M. leprae is incubated with cell lysates prepared from monocytes pre-labeled for 24 h with stearic C14 is strongly recommended. Also, based on the results shown in Figure 4, it would be expected a smaller number of bacilli being recovered from KO cells. So, why the signal of the hsp70 gene is similar in WT and KO cells? Finally, a second TLC showing the levels of labeled TAG in the host cell fraction will nicely complement the data. There are two slight bands above TAG in the WT infected cells that are also not seen in the GPAT3 KO. Would the authors believe that these are products derived of TAG utilization by M. leprae or other possible products related to GPAT3? Figure 4- Figures A-C show that GPAT3 KO is apparently affecting M. leprae internalization, since less bacteria is seen inside the cells at 24 h of infection. The reduced number of bacteria in KO cells could also be related to a decrease in mycobacterial viability. So, the inclusion of earlier time points of infection in the analysis shown in figures A-C, such as 4-6 h, is imperative and will definitively discriminate between these possibilities. If KO cells show less phagocytic capacity, as described in an earlier study referred in the discussion, this will absolutely compromise the conclusions drawn from figures 3 and 4. The reduction in LDs accumulation in the KO cells could be because less bacteria is infecting the cell and therefore less modulation of lipid metabolism is seen and not so much because of the absence of GPAT3. Concerning figure D, a detailed explanation of how bacterial viability is determined is missing in the methods section. In this case, different from figure 3, they mention that mRNA instead of DNA of the hsp70 gene was measured. Why? In these experiments they are also using a MOI of 200. Why? I couldn’t follow whether hsp70 was used to normalize potential differences in bacterial loads between WT and KO cells. I would advise to do a qRT-PCR, which is indeed more quantitative to evaluate viability percentages. Actually, in several other studies M. leprae viability has been determined by the 16S rRNA/16S rDNA ratio as described by Martinez AN et al, J Clin Microbiol. 2009; 47(7):2124–30. Discussion This section will need an extensive revision after the inclusion of new experiments as pointed out before. So far, the conclusions taken based on the assays with the GPAT-3 KO cells are not correct. The authors should also take into account the limitations imposed by their in vitro model based on THP-1 cells and discuss the discrepancies observed between their results and those generated by others along recent years. Previous studies have shown that in context of human primary monocytes, both live and dead M. leprae induces LDs accumulation. Also, infected primary monocytes were found enriched in cholesterol and cholesterol ester LDs, finding not confirmed in THP-1 cells. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-21795R1 Mycobacterium leprae promotes triacylglycerol de novo synthesis through induction of GPAT3 expression in human premonocytic THP-1 cells PLOS ONE Dear Dr. Suzuki, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 03 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Delphi Chatterjee Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The authors have responded to most comments and made the appropriate changes in the manuscript. However, few additional changes need to be included in the final version, as follows: 1-Authors should include details of the assay performed with dead bacteria to test the potential unspecific adsorption of TAG to M. leprae in the Materials and Methods section, such as the number of cells and bacteria used. 2-In figure 3C, imagens of uninfected wild type and KO cells stained with lipidTOX should be included. In the Discussion seccion: 3-The sentence “In this study, we performed a comprehensive lipid analysis using HPTLC to show that TAG is the main lipid that accumulates in lipid droplets in M. leprae-infected macrophages” needs to be changed. Their study did not perform “a comprehensive lipid analysis “. Moreover, as pointed out in the first round of review, macrophages should be replaced by THP-1 cells. 4-In the sentence “Primary cells infected with M. leprae are known to be rich in cholesterol and cholesterol esters, but not THP-1 cells [27]”, reference 27 refers just to the first part, not to THP-1 cells. Please make changes accordingly. 5- In the section where they speculate about the possible involvement of PPAR�, they should mention the study by Diaz Acosta CC et al. 2018, in which they show that this transcriptional factor is induced by M. leprae in infected Schwann cells and participates in host cell lipid accumulation. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Mycobacterium leprae promotes triacylglycerol de novo synthesis through induction of GPAT3 expression in human premonocytic THP-1 cells PONE-D-20-21795R2 Dear Dr. Suzuki, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Delphi Chatterjee Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-21795R2 Mycobacterium leprae promotes triacylglycerol de novo synthesis through induction of GPAT3 expression in human premonocytic THP-1 cells Dear Dr. Suzuki: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Delphi Chatterjee Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .